Yourgene Health PLC - Manchester-headquartered molecular diagnostics firm - Welcomes research article in Acta Clinica Belgica recommending screening in Belgium for dihydropyrimidine dehydrogenase deficiency, which can cause severe or even lethal side effects in patients undergoing treatment with chemotherapeutic drug 5-Fluorouracil. This drug is commonly used to treat cancers of the colon, stomach, oesophagus, breast, and cervix. Yourgene has a strong existing customer base and supplies its Elucigene DPYD test, which identifies cancer patients with dihydropyrimidine dehydrogenase deficiency, directly into Belgium.
Chief Executive Lyn Rees says: "The clinical value of DPYD screening is being increasingly recognised globally through such recommendations and we are in a strong position with our Elucigene DPYD test to support and expand into these markets. We are proud to already have an existing customer base in Belgium which we will continue to supply. We are pleased to see the wider recognition of the benefits of DPYD testing and the associated growth in market potential for our Elucigene DPYD test."
Current stock price: 13.90 pence
Year-to-date change: down 5.8%
By Anna Farley; annafarley@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
